Document Detail


Association between advanced Killip class at presentation and impaired myocardial perfusion among patients with ST-segment elevation myocardial infarction treated with primary angioplasty and adjunctive glycoprotein IIb-IIIa inhibitors.
MedLine Citation:
PMID:  19699865     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
BACKGROUND: Although primary angioplasty has been shown to improve survival as compared with thrombolysis, the outcome is still unsatisfactory in subsets of patients such as those with signs of heart failure at presentation. In fact, although primary angioplasty is able to restore TIMI 3 flow in most patients, suboptimal myocardial reperfusion is observed in a relatively large proportion of patients. The aim of this study was to investigate among patients with ST-segment elevation myocardial infarction undergoing primary angioplasty the association between heart failure at presentation and myocardial perfusion and its implications in terms of survival. METHODS: Our population is represented by patients undergoing primary angioplasty who are included in the EGYPT database. Congestive heart failure was defined as Killip class >1 at admission. Myocardial perfusion was evaluated by myocardial blush grade and ST-segment resolution. Follow-up data were collected between 30 days and 1 year after primary angioplasty. RESULTS: Detailed data on Killip class at presentation were available in 1,427 of 1,662 patients (86% of the initial population) who represent the final population of this study. Killip class was associated with myocardial perfusion, distal embolization, enzymatic infarct size, predischarge ejection fraction, and 1-year mortality rate. Myocardial blush was an independent predictor of 1-year mortality (hazard ratio 7.44, 95% CI 1.82-30.4, P = .005) in patients with advanced Killip class at presentation. CONCLUSIONS: Our study shows that patients with heart failure complicating ST-segment elevation myocardial infarction have impaired myocardial perfusion, which accounts for the poor outcome observed in these patients. Further efforts should be aimed at improving myocardial perfusion, beyond epicardial recanalization, to further improve the outcome of these high-risk patients.
Authors:
Giuseppe De Luca; C Michael Gibson; Kurt Huber; Uwe Zeymer; Dariusz Dudek; Donald Cutlip; Francesco Bellandi; Marko Noc; Ayse Emre; Simona Zorman; H Mesquita Gabriel; Mauro Maioli; Tomasz Rakowski; Mariann Gyöngyösi; Arnoud W J Van't Hof;
Related Documents :
11704375 - Interaction between smoking and the glycoprotein iiia p1(a2) polymorphism in non-st-ele...
17175045 - Cardiovascular magnetic resonance findings in typical versus atypical forms of the acut...
19411905 - Acute coronary syndrome.
11512695 - Dipyridamole-induced st-segment elevation indicative of transmural myocardial ischemia-...
24752415 - Change of the complexity of coronary artery disease after percutaneous coronary interve...
83625 - Persistent atrial standstill with atrial inexcitability.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American heart journal     Volume:  158     ISSN:  1097-6744     ISO Abbreviation:  Am. Heart J.     Publication Date:  2009 Sep 
Date Detail:
Created Date:  2009-08-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0370465     Medline TA:  Am Heart J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  416-21     Citation Subset:  AIM; IM    
Affiliation:
Division of Cardiology, "Maggiore della Carità" Hospital, Eastern Piedmont University, Novara, Italy. giuseppe.deluca@maggioreosp.novara.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Percutaneous coronary intervention in the Occluded Artery Trial: procedural success, hazard, and out...
Next Document:  Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials.